GE Healthcare Presents Positive Phase 2 Data with Flutemetamol - Phase 3
Program Now Underway

    



    
</pre>
<p><span class="xn-location">TORONTO</span>, <span class="xn-chron">April 9</span> /CNW/ -- GE Healthcare will today present results from its multicenter phase 2 study of flutemetamol at the 4th annual Human Amyloid Imaging (HAI) Meeting in <span class="xn-location">Toronto</span>, <span class="xn-location">Canada</span>. Flutemetamol is a positron emission tomography (PET) imaging agent in development by GE Healthcare, in the field of brain imaging.</p>
<p/>
<p>The purpose of the phase 2 study was to investigate the efficacy of flutemetamol in differentiating between patients with clinically probable Alzheimer's disease (AD) and cognitively intact healthy volunteers (HVs). In the study, subjects with a high probability of amyloid (27 AD patients) and a low probability of amyloid (25 healthy subjects) underwent PET imaging with flutemetamol. Five independent image readers, each blinded to the patient diagnosis, separately decided if each subject's image was normal or abnormal. The accuracy of image assessments was determined by comparing them to the subjects' diagnoses. In addition, 20 subjects with a memory disorder known as mild cognitive impairment (MCI), which may represent early AD, were enrolled and imaged with flutemetamol.</p>
<p/>
<p>"The availability of a tool such as [18F] Flutemetamol to identify amyloid in life could bring tremendous benefits to the field of Alzheimer's disease," said William E. Klunk, MD, PhD, Professor of Psychiatry and Neurology, University of <span class="xn-location">Pittsburgh</span>. "Increasing focus on the early diagnosis of this devastating disease and PET imaging might offer an opportunity to contribute to the knowledge base of the physician as we strive to progress novel treatment and management regimes for our patients."</p>
<p/>
<p>The flutemetamol phase 3 trial program is a series of multicenter studies that include patients who consent to brain biopsy or to post-mortem assays to determine the level of association between imaging detection and histopathology findings, as well as patients with MCI who may progress to AD. The trials have already commenced with recruitment and imaging of patients at multiple sites in the USA and <span class="xn-location">Europe</span>.</p>
<pre>
    

    About GE Healthcare
    
</pre>
<p>GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.</p>
<p/>
<p>Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the <span class="xn-location">United Kingdom</span>, GE Healthcare is a <span class="xn-money">$17 billion</span> unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at <a href="http://www.gehealthcare.com">www.gehealthcare.com</a>.</p>
<pre>
    




    

For further information: Nicole Nixon, JFK Communications, Inc. for GE Healthcare, [phone], [email protected] Web Site: http://www.gehealthcare.com